STAT Plus: Watch this company: Turning Point Therapeutics shares pop 57% after IPO

STAT Plus: Watch this company: Turning Point Therapeutics shares pop 57% after IPO

Play Episode Pause Episode

Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds

00:00 /

RSS Feed

Share

Link

Embed

A San Diego-based developer of targeted cancer drugs is hoping its medicine can shrink tumors in non-small cell lung cancer caused by specific genetic alterations.